Ascendis Pharma A/S (ASND), based in Copenhagen, Denmark, is a biopharmaceutical company that utilizes its proprietary TransCon technology platform to develop advanced therapeutics for ...

Novo Nordisk (NVO) has been granted an exclusive worldwide license to Ascendis Pharma’s (ASND) TransCon technology platform to develop its proprietary products in metabolic and cardiovascular ...

“We look forward to working with Ascendis to explore the potential of the TransCon technology platform to reduce the dosing frequency of GLP-1 receptor agonists and other treatments for ...

- The FDA grants Priority Review designation for the evaluation of medicines that, if approved, would provide a significant ...

TransCon CNP Ascendis proprietary TransCon technology platform. With the TransCon technology and our deep understanding of disease biology, it is possible to create medicine with highly ...

YORVIPATH is the second product developed with Ascendis Pharma’s TransCon technology platform to be launched commercially. “We are pleased to initiate the launch of YORVIPATH to address the ...

Also Read: Ascendis Pharma’s Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year The agreement includes provisions requiring certain TransCon technology-based ...

Under deal terms announced Monday, Ascendis, which is also based in Denmark, will conduct early development of the product candidates using its TransCon technology. Novo Nordisk will cover the ...

“Ascendis has leveraged its innovative TransCon technology platform to create a suite of highly differentiated product candidates with best-in-class potential that complement our existing pharma ...

“We look forward to working with Ascendis to explore the potential of the TransCon technology platform to reduce the dosing frequency of GLP-1 receptor agonists and other treatments for cardiome ...

Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of ...